Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

DMFS: Neoadjuvant Nivolumab Plus Ipilimumab versus Adjuvant Nivolumab in Resectable, Macroscopic Stage III Melanoma

Breaking Science in Skin Cancer Video Series

Login to get immediate access to this content.

Login

Speaker: Minke W. Lucas, Netherlands

Abstracts discussed:

  • LBA42 - Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: the NADINA trial: Watch the presentation from ESMO 2024 now

The speakers and studies featured in this video series were selected independently by ESMO.

Published October 2024

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.